In small test, experimental prostate drug shows promise

An experimental drug is showing what some experts say is intriguing effectiveness in treating a major cause of death and disability for men with prostate cancer — tumors that have spread to the bone.

The results of early testing of the drug, to be presented at a cancer conference in Berlin on Thursday, would be another piece of good news this week for men with the disease. On Wednesday, a federal advisory committee said there was adequate evidence that the already marketed prostate cancer drug Provenge, developed by Dendreon, prolongs lives.